Expression of uPA, tPA, and PAI-1 in calcified aortic valves

Biochemistry Research International

Volumn 2014, Issue , 2014, Pages

  Kochtebane, Najlah ^a   Alzahrani, Abdullah Mossa M ^b   Bartegi, Aghleb ^b  

^a BICHAT HOSPITAL   (France)

^b KING FAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84897809155     PISSN: 20902247     EISSN: 20902255     Source Type: Journal    
DOI: 10.1155/2014/658643     Document Type: Article

References (36)

1. Nkomo V. T., Gardin J. M., Skelton T. N., Gottdiener J. S., Scott C. G., Enriquez-Sarano M., Burden of valvular heart diseases: a population-based study. The Lancet 2006 368 9540 1005 1011 2-s2.0-33748453667 10.1016/S0140-6736(06) 69208-8 (Pubitemid 44353666)
2. Davies M. J., Treasure T., Parker D. J., Demographic characteristics of patients undergoing aortic valve replacement for stenosis: relation to valve morphology. Heart 1996 75 2 174 178 2-s2.0-0030027520 (Pubitemid 26069841)
3. Peterson M. D., Roach R. M., Edwards J. E., Types of aortic stenosis in surgically removed valves. Archives of Pathology and Laboratory Medicine 1985 109 9 829 832 2-s2.0-0022404426 (Pubitemid 16239908)
4. Dweck M. R., Boon N. A., Newby D. E., Calcific aortic stenosis A disease of the valve and myocardium. Journal of the American College of Cardiology 2012 60 19 1854 1863
5. Chan K.-L., Is aortic stenosis a preventable disease? Journal of the American College of Cardiology 2003 42 4 593 599 2-s2.0-0042731953 10.1016/S0735-1097(03)00786-1 (Pubitemid 37000171)
6. Lindroos M., Kupari M., Heikkila J., Tilvis R., Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. Journal of the American College of Cardiology 1993 21 5 1220 1225 2-s2.0-0027477079 (Pubitemid 23106200)
7. Fondard O., Detaint D., Iung B., Choqueux C., Adle-Biassette H., Jarraya M., Hvass U., Couetil J.-P., Henin D., Michel J.-B., Vahanian A., Jacob M.-P., Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors. European Heart Journal 2005 26 13 1333 1341 2-s2.0-26444473660 10.1093/eurheartj/ehi248 (Pubitemid 41435466)
8. Jacob M. P., Extracellular matrix remodeling and matrix metalloproteinases in the vascular wall during aging and in pathological conditions. Biomedicine and Pharmacotherapy 2003 57 5-6 195 202 2-s2.0-0042347601 10.1016/S0753-3322(03)00065-9 (Pubitemid 36897685)
9. Meilhac O., Ho-Tin-Noé B., Houard X., Philippe M., Michel J.-B., Anglés-Cano E., Pericellular plasmin induces smooth muscle cell anoikis. The FASEB Journal 2003 17 10 1301 1303 2-s2.0-0037590158
10. Collen D., Lijnen H. R., Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991 78 12 3114 3124 2-s2.0-0026331304
11. Blasi F., Vassalli J.-D., Dano K., Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. Journal of Cell Biology 1987 104 4 801 804 2-s2.0-0023197175 (Pubitemid 17068652)
12. Sidenius N., Blasi F., The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer and Metastasis Reviews 2003 22 2-3 205 222 2-s2.0-0038364216 10.1023/A:1023099415940 (Pubitemid 36561058)
13. Vassalli J.-D., The urokinase receptor. Fibrinolysis 1994 8 1 172 181 2-s2.0-0027981123 10.1016/0268-9499(94)90715-3 (Pubitemid 24287548)
14. Danø K., Andreasen P. A., Grøndahl-Hansen J., Kristensen P., Nielsen L. S., Skriver L., Plasminogen activators, tissue degradation, and cancer. Advances in Cancer Research 1985 44 139 266 2-s2.0-0021780949 10.1016/S0065-230X(08)60028-7
15. Ny T., Peng X.-R., Ohlsson M., Hormonal regulation of the fibrinolytic components in the ovary. Thrombosis Research 1993 71 1 1 45 2-s2.0-0027270450 10.1016/0049-3848(93)90203-Z (Pubitemid 23190628)
16. Andreasen P. A., Kjøller L., Christensen L., Duffy M. J., The urokinase-type plasminogen activator system in cancer metastasis. International Journal of Cancer 1997 72 1 22 (Pubitemid 27314632)
17. Pepper M. S., Sappino A.-P., Stocklin R., Montesano R., Orci L., Vassalli J.-D., Upregulation of urokinase receptor expression on migrating endothelial cells. Journal of Cell Biology 1993 122 3 673 684 2-s2.0-0027183188 (Pubitemid 23226684)
18. Rømer J., Bugge T., Pyke C., Lund L. R., Flick M. J., Degen J. L., Danø K., Impaired wound healing in mice with a disrupted plasminogen gene. Fibrinolysis 1996 2 287 292 2-s2.0-33846655236 (Pubitemid 26080649)
19. Del Rosso M., Fibbi G., Matucci Cerinic M., The urokinase-type plasminogen activator system and inflammatory joint diseases. Clinical and Experimental Rheumatology 1999 17 4 485 498 2-s2.0-0032875111 (Pubitemid 29343639)
20. Kruithof E. K. O., Plasminogen activator inhibitors-a review. Enzyme 1988 40 2-3 113 121 2-s2.0-0023677472
21. Schneiderman J., Loskutoff D. J., Plasminogen activator inhibitors. Trends in Cardiovascular Medicine 1991 1 3 99 102 2-s2.0-0025738266 10.1016/1050-1738(91)90001-U
22. Dawson S., Henney A., The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. Atherosclerosis 1992 95 2-3 105 117 2-s2.0-0026713962
23. Grondahl-Hansen J., Christensen I. J., Rosenquist C., Brunner N., Mouridsen H. T., Dano K., Blichert-Toft M., High levels of urokinase-type plasminogen activator and its inhibitor PAI- 1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Research 1993 53 11 2513 2521 2-s2.0-0027223048 (Pubitemid 23168015)
24. Hamsten A., Wiman B., De Faire U., Blomback M., Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. The New England Journal of Medicine 1985 313 25 1557 1563 2-s2.0-0022354051 (Pubitemid 16177394)
25. Meltzer M. E., Doggen C. J. M., De Groot P. G., Rosendaal F. R., Lisman T., Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men. Blood 2010 116 4 529 536 2-s2.0-77956022279 10.1182/blood-2010-01- 263103
26. Schneiderman J., Sawdey M. S., Keeton M. R., Bordin G. M., Bernstein E. F., Dilley R. B., Loskutoff D. J., Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proceedings of the National Academy of Sciences of the United States of America 1992 89 15 6998 7002 2-s2.0-0026650622 10.1073/pnas.89.15.6998
27. Stewart B. F., Siscovick D., Lind B. K., Gardin J. M., Gottdiener J. S., Smith V. E., Kitzman D. W., Otto C. M., Clinical factors associated with calcific aortic valve disease. Journal of the American College of Cardiology 1997 29 3 630 634 2-s2.0-0031051128 10.1016/S0735-1097(96)00563-3 (Pubitemid 27116107)
28. Nordt T. K., Peter K., Ruef J., Kubler W., Bode C., Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease. Thrombosis and Haemostasis 1999 82 supplement 1 14 18 2-s2.0-0033376209 (Pubitemid 30093624)
29. Raghunath P. N., Tomaszewski J. E., Brady S. T., Caron R. J., Okada S. S., Barnathan E. S., Plasminogen activator system in human coronary atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 1995 15 9 1432 1443 2-s2.0-0029092453
30. Lupu F., Bergonzelli G. E., Heim D. A., Cousin E., Genton C. Y., Bachmann F., Kruithof E. K. O., Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arteriosclerosis and Thrombosis 1993 13 7 1090 1100 2-s2.0-0027172704 (Pubitemid 23195812)
31. Cueff de Monchy C., Kochtebane N., Jacob M. P., Michel J. P., Zeitoun D. M., Rétrécissement valvulaire aortique: physiopathologie et implications thérapeutiques. Sang Thrombose Vaisseaux 2008 20 352 361
32. Pohle K., Mäffert R., Ropers D., Moshage W., Stilianakis N., Daniel W. G., Achenbach S., Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation 2001 104 16 1927 1932 2-s2.0-0035899912 (Pubitemid 32983236)
33. Mohler E. R. III, Gannon F., Reynolds C., Zimmerman R., Keane M. G., Kaplan F. S., Bone formation and inflammation in cardiac valves. Circulation 2001 103 11 1522 1528 2-s2.0-0035916929 (Pubitemid 32226259)
34. Kanno Y., Into T., Lowenstein C. J., Matsushita K., Nitric oxide regulates vascular calcification by interfering with TGF- β signalling. Cardiovascular Research 2008 77 1 221 230 2-s2.0-38849207866 10.1093/cvr/cvm049 (Pubitemid 351195162)
35. Fay W. P., Garg N., Sunkar M., Vascular functions of the plasminogen activation system. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 1231 1237 (Pubitemid 46809410)
36. Bouton M.-C., Boulaftali Y., Richard B., Arocas V., Michel J.-B., Jandrot-Perrus M., Emerging role of serpinE2/protease nexin-1 in hemostasis and vascular biology. Blood 2012 119 11 2452 2457 2-s2.0-84858650650 10.1182/blood-2011-10-387464